Vinge advised LumenRadio AB (publ) in connection with the listing on Nasdaq First North Growth Market

Vinge has advised LumenRadio AB (publ) (“LumenRadio”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 28 November 2022 and the first day of trading occurred on 8 December 2022.

The offering in connection with the listing was conducted at a fixed price of SEK 48 per share, corresponding to a market value for LumenRadio’s shares of approximately SEK 544 million before the offering and approximately SEK 594 million after the completion of the offering.

LumenRadio is a Gothenburg based technology company focusing on developing and selling reliable wireless product-to-product connections for business-critical applications within the Internet of Things (“IoT”). LumenRadio offers scalable solutions that build on proprietary and patented technology for future-proof wireless data transfer on open frequency bands, replacing traditional cables for control and automation. LumenRadio has around 60 employees and is headquartered in Gothenburg, with two small sales offices in Frankfurt and Boston.

Vinge’s team primarily consisted of Magnus Pauli, Edin Agic (Project Manager), Petronella Hallberg, Adrian Filipovic, Amelia Rihs, Hanna Jansson (Capital Markets and Public M&A), Anna Högsten, Victoria Gunnerek (Employment and Sanctions) and Amanda Stoltz (VDR).



Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023